US FDA approves durvalumab (Imfinzi) as 1st-line treatment for adult patients with extensive-stage small cell lung cancer

Approval was based on Phase III CASPIAN trial, in which risk of death was reduced by 27% with median overall survival of 13.0 months vs. 10.3 months for standard-of-care chemotherapy alone (etoposide and either carboplatin or cisplatin).

SPS commentary:

In the UK and EU, durvalumab is currently only licensed for treatment of unresectable, locally advanced, PDL-1≥ 1% non-small cell lung cancer - maintenance monotherapy after platinum-based chemotherapy